Mitigating the risk of transfusion‐transmitted infections with vector‐borne agents solely by means of pathogen reduction. Issue 7 (21st June 2022)

• Record Type: Journal Article
• Authors: Stramer, Susan L.; Lanteri, Marion C.; Brodsky, Jaye P.; Foster, Gregory A.; Krysztof, David E.; Groves, Jamel A.; Townsend, Rebecca L.; Notari, Edward; Bakkour, Sonia; Stone, Mars; Simmons, Graham; Spencer, Bryan; Tonnetti, Laura; Busch, Michael P.
• Is Part Of: Transfusion. Volume 62:Issue 7(2022)
• Page Start: 1388
• Page End: 1398
• Publication Date: 2022-06-21
• Subjects: Hematology -- Periodicals; Blood -- Transfusion -- Periodicals; Blood Group Antigens -- Periodicals; Blood Preservation -- Periodicals; Blood Transfusion -- Periodicals; 615
• DOI: 10.1111/trf.16950
• Languages: English
• ISSNs: 0041-1132

Abstract

Abstract: Background: This study evaluated whether pathogen reduction technology (PRT) in plasma and platelets using amotosalen/ultraviolet A light (A/UVA) or in red blood cells using amustaline/glutathione (S‐303/GSH) may be used as the sole mitigation strategy preventing transfusion‐transmitted West Nile (WNV), dengue (DENV), Zika (ZIKV), and chikungunya (CHIKV) viral, and Babesia microti, Trypanosoma cruzi, and Plasmodium parasitic infections. Methods: Antibody (Ab) status and pathogen loads (copies/mL) were obtained for donations from US blood donors testing nucleic acid (NAT)‐positive for WNV, DENV, ZIKV, CHIKV, and B. microti . Infectivity titers derived from pathogen loads were compared to published PRT log10 reduction factors (LRF); LRFs were also reviewed for Plasmodium and T. cruzi . The potential positive impact on donor retention following removal of deferrals from required questioning and testing for WNV, Babesia, Plasmodium, and T. cruzi was estimated for American Red Cross (ARC) donors. Results: A/UVA and S‐303/GSH reduced infectivity to levels in accordance with those recognized by FDA as suitable to replace testing for all agents evaluated. If PRT replaced deferrals resulting from health history questions and/or NAT for WNV, Babesia, Plasmodium, and T. cruzi, 27, 758 ARC donors could be retained allowing approximately 50, 000 additional donations/year based on 1.79 donations/donor for calendar year 2019 (extrapolated to an estimated 125, 000 additional donations nationally). Conclusion: Pathogen loads in donations from US blood donors demonstrated that robust PRT may provide an opportunity to replace deferrals associated with donor questioning and NAT for vector‐borne agents allowing for significant donor retention and likely increased blood availability.